Maxine Gowen Net Worth

The estimated Net Worth of Maxine Gowen is at least $2.99 Million dollars as of 1 June 2024. Maxine Gowen owns over 4,660 units of Trevena Inc stock worth over $127,038 and over the last 11 years he sold TRVN stock worth over $55,032. In addition, he makes $2,808,860 as Director at Trevena Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Maxine Gowen TRVN stock SEC Form 4 insiders trading

Maxine has made over 14 trades of the Trevena Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 4,660 units of TRVN stock worth $34,903 on 1 June 2024.

The largest trade he's ever made was exercising 124,477 units of Trevena Inc stock on 23 April 2014 worth over $84,644. On average, Maxine trades about 6,076 units every 63 days since 2014. As of 1 June 2024 he still owns at least 16,961 units of Trevena Inc stock.

You can see the complete history of Maxine Gowen stock trades at the bottom of the page.

Maxine Gowen biography

Dr. Maxine Gowen Ph.D. serves as Director of the Company. Prior to this Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. As Senior Vice President for the Center of Excellence for External Drug Discovery (CEEDD), she developed an innovative new approach to externalizing drug discovery in big pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in and served on the board of directors of numerous companies. Until 2002 Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK from 1989-1992. She has authored more than 100 refereed scientific publications. Dr. Gowen graduated with a B.Sc. in biochemistry from the University of Bristol, UK, then received a Ph.D. in cell biology from the University of Sheffield, UK, and received an MBA from the Wharton School of the University of Pennsylvania. Dr. Gowen served on the board of Human Genome Sciences until its purchase by GSK in July 2012. She currently serves on the board of Akebia Therapeutics, Inc. and Idera Pharmaceuticals, Inc., both public biopharmaceutical companies, since July 2014 and January 2016, respectively. Dr. Gowen also serves on the boards of the state and national biotechnology industry associations, Life Sciences PA and BIO, respectively. Our Board believes that Dr. Gowen’s detailed knowledge of our company and her over 20 years in the pharmaceutical industry, including her roles at GSK, provide a critical contribution to the Board.

What is the salary of Maxine Gowen?

As the Director of Trevena Inc, the total compensation of Maxine Gowen at Trevena Inc is $2,808,860. There are no executives at Trevena Inc getting paid more.

How old is Maxine Gowen?

Maxine Gowen is 62, he's been the Director of Trevena Inc since 2018. There are 3 older and 10 younger executives at Trevena Inc. The oldest executive at Trevena Inc is Anne Phillips, 66, who is the Independent Director.

What's Maxine Gowen's mailing address?

Maxine's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087.

Insiders trading at Trevena Inc

Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire, and Partners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.

What does Trevena Inc do?

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.

Complete history of Maxine Gowen stock trades at Aclaris Therapeutics Inc, Akebia Therapeutics, Idera Pharmaceuticals, Merus N.V, Trevena Inc, and Passage Bio Inc

Trevena Inc executives and stock owners

Trevena Inc executives and other stock owners filed with the SEC include:

• Maxine Gowen,
  Director
• Carrie Bourdow,
  President, Chief Executive Officer, Director
• Carrie L. Bourdow,
  Pres, CEO & Director
• Mark Demitrack,
  Senior Vice President and Chief Medical Officer
• Dr. Mark A. Demitrack,
  Sr. VP & Chief Medical Officer
• Robert Yoder,
  Senior Vice President and Chief Business Officer
• Dan Ferry,
  IR Contact Officer
• Scott Applebaum,
  Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs
• Barbara Yanni,
  Independent Director
• Anne Phillips,
  Independent Director
• Jake Nunn,
  Independent Director
• Julie McHugh,
  Independent Director
• Michael Dougherty,
  Independent Director
• Scott Braunstein,
  Independent Director
• Barry Shin,
  Chief Financial Officer, Senior Vice President
• Leon Moulder,
  Independent Chairman of the Board
• Patricia M. Drake,
  Chief Commercial Officer
• Robert T. Yoder,
  Sr. VP, Chief Bus. Officer & Head of Commercial Operations
• Barry Shin,
  Sr. VP & CFO
• Michael Catalano,
  VP of Marketing
• Dr. Howard A. Rockman M.D.,
  Scientific Founder, Consultant and Member of Scientific Advisory Board
• John P. Hamill,
  VP Fin,Princ Fin&Acct Officer
• Marvin Johnson,
  Director
• Michael W. Lark,
  Sr. VP, Research & CSO
• Jason Raleigh Nunn,
  Director
• Adam Koppel,
  Director
• Yacoub Habib,
  SVP, Bus Dev & Corp Planning
• Roberto Cuca,
  Sr. VP and CFO
• David Soergel,
  Sr. VP, Clinical Development
• John M Limongelli,
  Sr. VP,General Counsel & Secy
• Jonathan Violin,
  SVP-Scientific Affairs & IR
• David Geoghegan,
  Sr. VP, Operations
• Partners Viii, L.P.Alta Par...,
  
• Francois Nader,
  Director
• Venture Management Co. V, L...,
  
• Farah Champsi,
  Director
• Robert Prachar,
  Sr. VP, Corp. Strategy
• David F Solomon,
  Director
• Rosamond Deegan,
  Sr VP, Bus Dev & Operations
• Laboratories Holdings Ltd F...,
  
• Terrance Mcguire,
  Director
• Ventures Viii, L.P.Cavanaug...,
  
• Venture Management Co. V, L...,
  
• Patricia M. Drake,
  SVP, Chief Commercial Officer
• Mark Corrigan,
  Director